Ryan Barbara

Director Ryan Barbara purchased 8 shares of INDV at $31.08 on 2026-03-13, raising holdings to 5,724 shares.

Ryan Barbara, a director at Indivior Pharmaceuticals, bought 8 shares at $31.08, a minimal addition to his 5,716-share position. The transaction is modest in absolute terms, totaling $248.68 and representing a 0.1% increase to his holdings. At the current price of $31.11, INDV trades near the transaction level but significantly below its 52-week high of $36.60, having declined 15.0% from that peak. The company's fundamentals show reasonable health—$314.0M quarterly revenue, $42.0M net income, 4.3% annual revenue growth, and a P/E ratio of 11.74—but the stock's recent weakness (down 8.7% over 30 days and 12.5% over 90 days) and Barbara's prior purchase 4 days earlier on 2026-03-09 suggest opportunistic accumulation during a downturn rather than a material confidence signal.

Director Ryan Barbara bought 31 shares of INDV at $32.56 for $1.0K, adding to 5.7K-share position.

Ryan Barbara, a director of Indivior Pharmaceuticals, purchased 31 shares at $32.56 on 2026-03-09, a modest addition representing +0.5% of his pre-transaction holdings. The stock currently trades at $32.83, near where he bought it, and has declined 10.3% from its 52-week high and 3.0% over the prior 30 days. In his cross-ticker track record, prior buys averaged a -3.0% return at the 30-day mark, and his sole prior purchase at INDV on 2026-01-05 also showed a -3.0% 30-day return. The company's fundamentals remain modest but stable: $314.0M quarterly revenue, $42.0M net income, 4.3% annual revenue growth, and a P/E of 12.39. The small share count and dollar value ($1.0K) suggest this is routine portfolio activity rather than a significant conviction signal.

Director Ryan Barbara bought 775 INDV shares at $35.39; part of 4-insider cluster buy in past 14 days.

Ryan Barbara (Director) purchased 775 shares at $35.39, increasing his holdings by 65.2% from 1,188 to 1,963 shares—a material accumulation for a board member. This transaction is part of a cluster pattern, with 4 other insiders also buying within the past 14 days, suggesting coordinated confidence at a price point ($35.39) very near the 52-week high of $36.60. The company's fundamentals show solid performance: $314.0M quarterly revenue, $42.0M net income, and 8.7% annual revenue growth, though the 36.25 P/E reflects a premium valuation. The clustering of director-level accumulation, combined with the substantial individual position increase, is notable for tracking insider conviction in the current environment.